An 8-Week, Double-Blind, Placebo-Controlled, Multicenter Study With Paroxetine (20 mg q24) as Positive Control, Evaluating the Efficacy and Safety of 2 Fixed Doses of SR58611A (175 mg q12 and 350 mg q12) in Outpatients With GAD.

Trial Profile

An 8-Week, Double-Blind, Placebo-Controlled, Multicenter Study With Paroxetine (20 mg q24) as Positive Control, Evaluating the Efficacy and Safety of 2 Fixed Doses of SR58611A (175 mg q12 and 350 mg q12) in Outpatients With GAD.

Completed
Phase of Trial: Phase III

Latest Information Update: 21 Jul 2011

At a glance

  • Drugs Amibegron (Primary)
  • Indications Generalised anxiety disorder
  • Focus Therapeutic Use
  • Sponsors Sanofi
  • Most Recent Events

    • 02 Nov 2008 Trial end date (1 Apr 2007) added as reported by ClinicalTrials.gov.
    • 02 Nov 2008 Actual start date changed from 1 Jan 2006 to 1 Mar 2006 as reported by ClinicalTrials.gov.
    • 02 Nov 2008 Actual patient number (508) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top